Teladoc Health Valuation

Is TDOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TDOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TDOC ($9.04) is trading below our estimate of fair value ($26.79)

Significantly Below Fair Value: TDOC is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TDOC?

Other financial metrics that can be useful for relative valuation.

TDOC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA29.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TDOC's PS Ratio compare to its peers?

The above table shows the PS ratio for TDOC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.2x
NXGN NextGen Healthcare
2.3x6.7%US$1.6b
CERT Certara
4.9x10.7%US$1.8b
SDGR Schrödinger
6.4x17.3%US$1.3b
PHR Phreesia
3.3x11.9%US$1.3b
TDOC Teladoc Health
0.6x0.8%US$1.5b

Price-To-Sales vs Peers: TDOC is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (4.8x).


Price to Earnings Ratio vs Industry

How does TDOC's PE Ratio compare vs other companies in the US Healthcare Services Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: TDOC is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Healthcare Services industry average (2.1x).


Price to Sales Ratio vs Fair Ratio

What is TDOC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TDOC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: TDOC is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TDOC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.04
US$9.95
+10.1%
20.3%US$17.00US$8.00n/a20
Sep ’25US$7.17
US$9.76
+36.1%
21.0%US$17.00US$8.00n/a21
Aug ’25US$8.59
US$12.38
+44.1%
36.9%US$25.00US$8.00n/a21
Jul ’25US$9.32
US$16.52
+77.3%
24.0%US$25.00US$10.00n/a21
Jun ’25US$11.24
US$16.76
+49.1%
22.5%US$25.00US$10.00n/a21
May ’25US$12.81
US$17.38
+35.7%
19.1%US$25.00US$12.00n/a22
Apr ’25US$14.85
US$20.36
+37.1%
17.8%US$28.00US$16.00n/a22
Mar ’25US$15.00
US$20.52
+36.8%
17.7%US$28.00US$16.00n/a21
Feb ’25US$19.84
US$23.03
+16.1%
18.7%US$34.00US$16.00n/a20
Jan ’25US$21.55
US$22.80
+5.8%
20.8%US$34.00US$16.00n/a19
Dec ’24US$18.97
US$22.80
+20.2%
20.8%US$34.00US$16.00n/a19
Nov ’24US$16.65
US$23.54
+41.4%
21.9%US$34.00US$16.00n/a19
Oct ’24US$18.59
US$29.54
+58.9%
16.1%US$40.00US$20.00US$8.8619
Sep ’24US$22.87
US$30.11
+31.7%
13.8%US$40.00US$25.00US$7.1721
Aug ’24US$27.75
US$30.06
+8.3%
14.0%US$40.00US$25.00US$8.5921
Jul ’24US$25.32
US$30.35
+19.9%
12.6%US$40.00US$25.00US$9.3222
Jun ’24US$23.83
US$30.40
+27.6%
12.5%US$40.00US$25.00US$11.2422
May ’24US$27.07
US$30.30
+11.9%
13.0%US$40.00US$23.00US$12.8122
Apr ’24US$25.90
US$30.08
+16.1%
13.8%US$40.00US$23.00US$14.8521
Mar ’24US$25.88
US$31.08
+20.1%
13.2%US$40.00US$25.00US$15.0021
Feb ’24US$30.74
US$32.21
+4.8%
14.9%US$45.00US$24.00US$19.8422
Jan ’24US$23.65
US$32.83
+38.8%
14.6%US$45.00US$24.00US$21.5524
Dec ’23US$29.00
US$32.95
+13.6%
14.6%US$45.00US$24.00US$18.9724
Nov ’23US$28.88
US$33.04
+14.4%
14.6%US$45.00US$24.00US$16.6524
Oct ’23US$25.35
US$36.08
+42.3%
16.8%US$55.00US$25.00US$18.5925

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies